{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104545","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.168180+00:00","generated_at":"2026-05-17T18:12:14.339062+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monte Rosa Q2 net loss narrows to $12.3M on $23.2M collaboration revenue; cash runway to 2028","bullets":["Collaboration revenue $23.2M (vs $4.7M YoY) from Novartis license; net loss improved to $12.3M from $30.3M.","R&D $30.7M, G&A $8.1M; cash $295.5M (down $35.5M from Q1), expected to fund into 2028.","Phase 1 of NEK7-directed MGD MRT-8102 dosed; initial data expected H1 2026 for inflammatory diseases.","MRT-6160 advancing toward multiple Phase 2 studies with Novartis; potential milestones up to $2.1B."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104545","json":"https://secwatch.observer/filing/0000950170-25-104545.json","markdown":"https://secwatch.observer/filing/0000950170-25-104545.md","text":"https://secwatch.observer/filing/0000950170-25-104545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/0000950170-25-104545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/glue-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:12:14.339062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}